Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

NCT07449039 | Recruiting FDA Device

• 1 other identifier: 25-0020
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes. Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.

Conditions

Gestational Diabetes Mellitus in Pregnancy

Outcome Measures

Primary Outcomes (2)

• Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test

  Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT

  24 hours postpartum and 1-3 months postpartum

• Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum

  Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c

  24 hours postpartum and 1-3 months postpartum

Secondary Outcomes (1)

• Patient satisfaction with CGM use immediately postpartum to evaluate long term risk

  1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test

Study Arms (1)

Continuous Glucose Monitor

OTHER

Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data.

Device: Continuous Glucose Monistor

Interventions

Continuous Glucose Monistor DEVICE

Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off.

Also known as: Dexcom G7

Continuous Glucose Monitor

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Prenatal care at UCLA Health
• Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
• Confirmed gestational diabetes diagnosis based on 2-step approach
• Maternal age \>= 18 years

You may not qualify if:

• Pre-gestational diabetes (T1DM or T2DM)
• Multifetal gestation
• Intra-amniotic infection by clinical criteria
• Postpartum hemorrhage
• Maternal ICU admission
• Known allergy to medical-grade adhesive
• Presence of skin lesions at anticipated CGM application site
• Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
• Metformin use
• Steroid use
• Terbutaline use within 4 hours of delivery
• Cystic fibrosis
• MODY (mature onset of diabetes in the young)

Sponsors & Collaborators

• University of California, Los Angeles: lead

Study Sites (1)

University of California, Los Angeles

Los Angeles, California, 90095, United States

RECRUITING

Study Officials

• Christina Han, MD

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rujuta Sathe

CONTACT

310-794-8893; RSathe@mednet.ucla.edu

Dana Levin-Lopez, MPH

CONTACT

310-794-8893; dlevinlopez@mednet.ucla.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Division Director, Maternal-Fetal Medicine

Model Details: This study will follow a within-subjects design where participants will serve as their own control group.

Study Record Dates

• First Submitted: December 18, 2025
• First Posted: March 4, 2026
• Study Start: September 28, 2025
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): June 1, 2030
• Last Updated: March 4, 2026

Record last verified: 2026-02

Locations

US (1)